冻干麻疹-腮腺炎-风疹三联活疫苗免疫安全性及免疫学效果观察

目的 观察卫生部北京生物制品研究所研制的麻疹-腮腺炎-风疹（北京MMR）疫苗的免疫学效果。方法 分别选择10-12岁，2-2.5岁和8-12月龄儿童，接种北京MMR（实验疫苗），并与进口MMR疫苗，麻疹疫苗，腮腺炎疫苗和风疹疫苗（对照疫苗）相比较，开展该疫苗的免疫安全性和免疫原性观察研究。结果 在32名2岁以上较大龄儿童接种北京MMR疫苗无副反应发生后，对104名8-12月龄婴儿接种该疫苗，仅有6.7%和1.9%的儿童分别发生一过性发热（中低反应）和皮疹，无其他不良反应发生，北京MMR疫苗免疫接种后，其麻疹，风疹，腮腺炎HI抗体阳转率分别为100%，100%和85.7%;GMT分别为41，320和6.1，分别与对照疫苗相比，差异多无显著性。结论 北京MMR疫苗具有与目前使用的麻疹疫苗，腮腺炎疫苗，风疹疫苗及进口MMR疫苗相同的免疫安全性和免疫原性，且可以作为麻疹的基础免疫和复种疫苗使用。

Studies on the safety and immunogenicity of lyophilized live attenuated measles-mumps-rubella combined vaccine

Objective To study the safety and immunogenicity of the measles mumps rubella combined vaccine (MMR) produced by Beijing Biological Product Institute. Methods Children aged 10 12 years, 2 2.5 years and 8 12 months were selected to be vaccinated with Beijing MMR vaccine(test vaccine). Other groups of children with similar nature were vaccinated with measles vaccine, mumps vaccine and rubella vaccine while using imported MMR vaccine (control vaccine) as controls. Results The safety of the Beijing MMR vaccine was confirmed after vaccinating 32 children above 2 years old. Among 104 children of 8 12 months were vaccinated with Beijing MMR vaccine, only 6.7 % of the children had transient fever and 1.9 % had signs of rashes but with no other signs observed. The positive seroconversion rates of measles, rubella and mumps anti HI were 100%, 100% and 85.7% respectively. GMT also showed high lever. Conclusion The MMR vaccine (Beijing) had good safety and immunogenicity which might be used to be the bases enhance immunization of measles.